Success Metrics

Clinical Success Rate
82.0%

Based on 351 completed trials

Completion Rate
82%(351/428)
Active Trials
65(10%)
Results Posted
49%(171 trials)
Terminated
77(12%)

Phase Distribution

Ph phase_2
241
36%
Ph phase_4
110
17%
Ph early_phase_1
27
4%
Ph phase_3
126
19%
Ph phase_1
79
12%
Ph not_applicable
82
12%

Phase Distribution

106

Early Stage

241

Mid Stage

236

Late Stage

Phase Distribution665 total trials
Early Phase 1First-in-human
27(4.1%)
Phase 1Safety & dosage
79(11.9%)
Phase 2Efficacy & side effects
241(36.2%)
Phase 3Large-scale testing
126(18.9%)
Phase 4Post-market surveillance
110(16.5%)
N/ANon-phased studies
82(12.3%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

74.1%

351 of 474 finished

Non-Completion Rate

25.9%

123 ended early

Currently Active

65

trials recruiting

Total Trials

666

all time

Status Distribution
Active(74)
Completed(351)
Terminated(123)
Other(118)

Detailed Status

Completed351
unknown114
Terminated77
Withdrawn46
Recruiting44
Active, not recruiting21

Development Timeline

Analytics

Development Status

Total Trials
666
Active
65
Success Rate
82.0%
Most Advanced
Phase 4

Trials by Phase

Early Phase 127 (4.1%)
Phase 179 (11.9%)
Phase 2241 (36.2%)
Phase 3126 (18.9%)
Phase 4110 (16.5%)
N/A82 (12.3%)

Trials by Status

completed35153%
unknown11417%
not_yet_recruiting91%
withdrawn467%
suspended41%
terminated7712%
recruiting447%
active_not_recruiting213%

Recent Activity

Clinical Trials (666)

Showing 20 of 666 trialsScroll for more
NCT03514108Phase 4

DANHEART (H-HeFT and Met-HeFT)

Completed
NCT03295383Phase 3

Randomized Clinical Trial Comparing the Safety and Efficacy of Rituximab Versus Oral Cyclophosphamide in Severe Forms of Mucous Membrane Pemphigoid

Active Not Recruiting
NCT04098666Phase 2

Metformin in Alzheimer's Dementia Prevention

Active Not Recruiting
NCT04262206Phase 4

Pragmatic Evaluation of Events And Benefits of Lipid-lowering in Older Adults

Recruiting
NCT06350630Phase 2

Therapeutic Effect of Hydroxychloroquine on Immunoglobulin A (IgA) Nephropathy Course QUIgAN Study

Recruiting
NCT04224493Phase 3

A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma.

Active Not Recruiting
NCT07611019Phase 2

Colchicine for the Prevention of Post-Operative Atrial Fibrillation After Coronary Artery Bypass Grafting: A Single-Center, Strategy-Stratified, Randomized, Double-Blind, Placebo-Controlled Trial

Not Yet Recruiting
NCT04232683Early Phase 1

Preoperative Tamsulosin to Prevent Postoperative Urinary Retention After Surgery For Pelvic Floor Disorders

Completed
NCT03722680Phase 2

Effectiveness Assessment of Riluzole in the Prevention of Oxaliplatin-induced Peripheral Neuropathy.

Suspended
NCT04059172Early Phase 1

Efficacy of Combined Ibuprofen and Acetaminophen Therapy Versus Ibuprofen Alone Versus Placebo Alone for Pain Management

Recruiting
NCT05888922Phase 3

Evaluation of Efficacy and Safety of Oral Minoxidil 1 mg in Female Androgenetic Alopecia

Recruiting
NCT04257929Phase 2

A Phase 2 Study to Evaluate the Safety and Efficacy of Pitolisant in Patients With Prader-Willi Syndrome, Followed by an Open Label Extension

Completed
NCT06563895Phase 3

Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant

Recruiting
NCT03865927Phase 2

GKT137831 in IPF Patients With Idiopathic Pulmonary Fibrosis

Completed
NCT04360681Phase 2

Lofexidine Combined With Buprenorphine for Reducing Symptoms of PTSD and OU Relapse in Veterans

Completed
NCT06704594Phase 4

Allopregnanolone and Dynamic GABA-A Receptor Plasticity in Selective Serotonin Reuptake Inhibitor Responsive Premenstrual Dysphoric Disorder

Recruiting
NCT04429516Phase 3

Morphine Sulfate/Placebo for the Treatment of PulmonAry Fibrosis Cough

Completed
NCT04136353Phase 3

Darolutamide Augments Standard Therapy for Localised Very High-Risk Cancer of the Prostate

Active Not Recruiting
NCT03581773Phase 2

Folic Acid Supplement Versus Placebo for Treating Mucositis Adverse Events in Metastatic Renal Cell Carcinoma Patients Receiving Targeted Therapy

Recruiting
NCT04659317Phase 3

Opioid-Free Orthopaedics

Recruiting

Drug Details

Intervention Type
DRUG
Total Trials
666